Navigation Links
GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
Date:11/11/2013

LONDON, Nov. 11, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW") a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme (GBM).

Glioma describes any tumor that arises from the glial tissue of the brain. GBM is a particularly aggressive tumor that forms from abnormal growth of glial tissue. According to the New England Journal of Medicine, GBM accounts for approximately 50% of the 22,500 new cases of brain cancer diagnosed in the United States each year. Treatment options are limited and expected survival is a little over one year. GBM is considered a rare, or orphan, disease by the FDA and the European Medicines Agency, or EMA.

This study follows several years of pre-clinical research conducted by GW in the field of glioma which has demonstrated that cannabinoids inhibit the viability of glioma cells both in vitro and in vivoi,ii via apoptosis or programmed cell death, may also affect angiogenesis, and have demonstrated tumor growth-inhibiting action and an improvement in the therapeutic efficacy of temozolomide, a standard treatment for glioma. In addition, GW has shown tumor response to be positively associated with tissue levels of cannabinoids. GW has identified the putative mechanism of action for our cannabinoid product candidate, where autophagy and programmed cell death are stimulated via stimulation of the TRB3 pathway.

"We are very excited about moving this compound into further human study and the prospects of cannabinoids as new anti-cancer treatments. This is GW's first clinical study of cannabinoids as a potential treatment to inhibit tumor growth," stated Dr. Stephen Wri
'/>"/>

SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 30, 2015 Nitto Avecia, a ... its increased capacity and production capability to serve ... variety and service fulfillment continues to drive Nitto ... process throughput capacities. , In Fall ... downstream process equipment at its Milford, MA facility, ...
(Date:4/30/2015)... , April 30, 2015 The following is an ... Directors of China Cord Blood Corp (NYSE: CO ) ... committee of the independent directors of China Cord Blood Corp ... offer of $6.40 per share from Golden Meditech Holdings Co ... per share would greatly benefit Golden Med and Mr. Kam, ...
(Date:4/30/2015)...  The Paul G. Allen Family Foundation announced today ... six groups of researchers with projects at the frontier ... growing mature human brain cells in the laboratory. The ... over three years.  "This new cohort ... significant because the field of neuronal maturation is at ...
(Date:4/30/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a ... medicine, today announced that it will release first quarter ... after the close of the U.S. financial markets. The ... Thursday, May 7, 2015 at 4:30 p.m. Eastern / ... corporate developments. For both "listen-only" participants and ...
Breaking Biology Technology:Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 2April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 4April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 5The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3
... PAREXEL International,Corporation (Nasdaq: PRXL ), ... Imogene Grimes, Ph.D., to Vice President of,Data ... biostatistician,with more than 25 years of experience, ... data science services, including data management,biostatistics, and ...
... LLC announced today,that it is teaming up with ... diabetes screenings to school age children in the ... pre-diabetic children and,adolescents. Beginning May 1, 2008 and ... be available free of charge at any of ...
... FRANCISCO, Calif., April 29 ,Anesiva, Inc. (Nasdaq: ... and distribution agreement, with Green Vision Company, for,several ... injection system is approved in the U.S. to,provide ... or blood,draws in children three to 18 years ...
Cached Biology Technology:PAREXEL Appoints Leading Biostatistician Dr. Imogene Grimes to Vice President of Data Sciences Strategic Services 2PAREXEL Appoints Leading Biostatistician Dr. Imogene Grimes to Vice President of Data Sciences Strategic Services 3PAREXEL Appoints Leading Biostatistician Dr. Imogene Grimes to Vice President of Data Sciences Strategic Services 4RediClinic, BIOSAFE Labs and Glycemion to Provide Free Diabetes Risk Assessments to Richmond, Va. School Children 2RediClinic, BIOSAFE Labs and Glycemion to Provide Free Diabetes Risk Assessments to Richmond, Va. School Children 3RediClinic, BIOSAFE Labs and Glycemion to Provide Free Diabetes Risk Assessments to Richmond, Va. School Children 4RediClinic, BIOSAFE Labs and Glycemion to Provide Free Diabetes Risk Assessments to Richmond, Va. School Children 5Anesiva Announces New Zingo Marketing and Distribution Agreement 2Anesiva Announces New Zingo Marketing and Distribution Agreement 3
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
(Date:4/1/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market, announces the second shipment of a ... early access pre-order customers. Feedback from ... including Walmart, Target, AT&T, Dunkin, Donuts, Stop & Shop ... all outlets and very easy to use. Several users ...
(Date:3/30/2015)... 26, 2015 Research and Markets ( ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... the Global Gesture Recognition market in Automotive Sector to ... 2013-2018. Gesture recognition is the ability of ... of an individual. Gesture recognition technology can be 2D-based ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... with the current poaching rates. The loss of this megaherbivore is ... on the ecosystems they now live in. The white ... of ecosystem functioning because theyre not controlled by predation. A ... Journal of Ecology , highlights the role of the white ...
... better be sure that there are no great tits around to ... So says Anders Brodin and Utku Urhan of the University of ... position of such hideaways up to 24 hours after seeing it ... well-known hoarders such as crows and jays, they do not store ...
... genetic traits in cattle that might allow farmers to ... The study, which compared the genetic code of ... to impact on a disease that leads to major ... University of Edinburgh,s Roslin Institute, has identified a number ...
Cached Biology News:Poaching threatens savannah ecosystems 2"You hide it -- I'll find it!" -- Great tit has a bird's eye view when looking for dinner 2Genetic find might lead to cattle that are more resistant to TB 2
RAT ANTI MOUSE METALLOPHILIC MACROPHAGES...
... All MagCellect Ferrofluid products ... conjunction with R&D Systems MagCellect ... capacities, this neodymium iron boron ... 12 x 75 mm test ...
Request Info...
Form: Concentrated Applications: ELISA...
Biology Products: